Examples of using Fpp in English and their translations into Hebrew
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
-
Programming
Boro fpp 02.
License type Full packaged product(FPP).
The specification(s) for the FPP should be provided.
The FPP manufacturer's test results should be summarized in the QOS-PD.
One complete copy of the PD should be provided for each FPP strength.
The production line BORO FPP 02 for the production of pyrolysis fuel.
The analytical procedures used for testing the FPP should be provided.
A specified impurity present in the existing API is considered qualified if the amount of the impurityin the existing API reflects the levels observed in the innovator or prequalified FPP.
Reference standards or materials- information on the FPP manufacturer's reference standards.
Primary packaging componentsare those that are in direct contact with the API or FPP.
It establishes the set of criteria to which an API or FPP should conform to be considered acceptable for its intended use.
These tables should be used to summarize the analytical procedures used for determination of the assay,related substances and dissolution of the FPP.
Overages for the sole purpose of extending the shelf-life of the FPP are generally not acceptable.
In cases where there is more than one API manufacturer, the FPP manufacturer's API specifications should be one single compiled set of specifications that is identical for each manufacturer.
Levels of impurities generated from studies under accelerated or stressed storage conditions of the innovator orprequalified FPP are not considered acceptable/qualified.
Where a pharmacopoeia standard is claimed for the API and/or the FPP, the primary reference standard should be obtained from that pharmacopoeia when available.
Information should be provided on the reference standard(s) used to generate data in the PD, as well as those to be used by the FPP manufacturer in routine API and FPP testing.
For APIs that are not BCS highly soluble contained in solid FPPs, or liquid FPPs containing undissolved API, the particle size distribution of the material can have an effect on thein vitro and/or in vivo behaviour of the FPP.
Copies should be provided of the validation reports for the analytical procedures used to generate testing results provided in the PD,as well as those proposed for routine testing of the API by the FPP manufacturer.
The declaration of access for the CEP should beduly filled out by the CEP holder on behalf of the FPP manufacturer or applicant to the WHO Prequalification of Medicines Programmed who refers to the CEP.
When an API is chiral, it should be specified whether specific stereoisomers or a mixture of stereoisomers have been used in the comparative biostudies, and information should be given as to thestereoisomer of the API that is to be used in the FPP.
The scientific rationale for the choiceof the manufacturing, filling and packaging processes that can influence FPP quality and performance should be explained(e.g. wet granulation using high shear granulator).
Copies of the API specifications, dated and signed by authorized personnel(e.g. the person in charge of the quality control or quality assurance department) should be provided in the PD,including specifications from each API manufacturer as well as those of the FPP manufacturer.
The stability programme also includes the studyof product related factors that influence the quality of the API or FPP, for example, interaction of API with excipients, container-closure systems and packaging materials.
A copy of the FPP specification(s) from the applicant(as well as the company responsible for the batch release of the FPP, if different from the applicant), dated and signed by authorized personnel(i.e. the person in charge of the quality control or quality assurance department) should be provided in the PD.
If samples of the innovator product are not available, the impurity profile mayalso be compared to a different prequalified FPP with the same route of administration and similar characteristics(e.g. tablet versus capsule).
The tables in the QOS-PD template shouldbe used to summarize the batch formula of the FPP for each proposed commercial batch size and to express the quantity of each component on a per batch basis, including a statement of the total weight or measure of the batch.
As outlined in the WHO stability guidelines, the purpose of stability testing is toprovide evidence of how the quality of an API or FPP varies with time under the influence of a variety of environmental factors such as temperature, humidity and light.
As outlined in the WHO stability guidelines(WHO Technical Report Series, No. 953, Annex 2, 2009),a single primary stability batch of the FPP should be tested for effectiveness of the antimicrobial preservative(in addition to preservative content) at the proposed shelf-life for verification purposes, regardless of whether there is a difference between the release and shelflife acceptance criteria for preservative content.
If“protect from light” is stated inone of the officially recognized pharmacopoeias for the API or FPP it is sufficient to state“protect from light” on labelling, in lieu of photo stability studies, when the container-closure system is shown to be light protective.
